scholarly journals Numerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences

2019 ◽  
Vol 11 ◽  
pp. 175628721985230 ◽  
Author(s):  
Matthijs J. Scheltema ◽  
Tim J. O’Brien ◽  
Willemien van den Bos ◽  
Daniel M. de Bruin ◽  
Rafael V. Davalos ◽  
...  

Background: At present, it is not possible to predict the ablation zone volume following irreversible electroporation (IRE) for prostate cancer (PCa). This study aimed to determine the necessary electrical field threshold to ablate human prostate tissue in vivo with IRE. Methods: In this prospective multicenter trial, patients with localized PCa were treated with IRE 4 weeks before their scheduled radical prostatectomy. In 13 patients, numerical models of the electrical field were generated and compared with the ablation zone volume on whole-mount pathology and T2-weighted magnetic resonance imaging (MRI) sequences. Volume-generating software was used to calculate the ablation zone volumes on histology and MRI. The electric field threshold to ablate prostate tissue was determined for each patient. Results: A total of 13 patients were included for histological and simulation analysis. The median electrical field threshold was 550 V/cm (interquartile range 383–750 V/cm) for the software-generated histology volumes. The median electrical field threshold was 500 V/cm (interquartile range 386–580 V/cm) when the ablation zone volumes were used from the follow-up MRI. Conclusions: The electrical field threshold to ablate human prostate tissue in vivo was determined using whole-mount pathology and MRI. These thresholds may be used to develop treatment planning or monitoring software for IRE prostate ablation; however, further optimization of simulation methods are required to decrease the variance that was observed between patients.

2001 ◽  
Vol 45 (6) ◽  
pp. 973-980 ◽  
Author(s):  
Mark G. Swanson ◽  
Daniel B. Vigneron ◽  
Tuan-Khanh C. Tran ◽  
Napapon Sailasuta ◽  
Ralph E. Hurd ◽  
...  

2021 ◽  
Vol 7 (2) ◽  
pp. 025017
Author(s):  
Olof A Lindahl ◽  
Tomas Bäcklund ◽  
Kerstin Ramser ◽  
Per Liv ◽  
Börje Ljungberg ◽  
...  

1999 ◽  
Vol 27 (5) ◽  
pp. 362-367 ◽  
Author(s):  
Julie Ellerhorst ◽  
Patricia Troncoso ◽  
Xiao-Chun Xu ◽  
Jack Lee ◽  
Reuben Lotan

ISRN Oncology ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Anastasia V. Suhovskih ◽  
Lyudmila A. Mostovich ◽  
Igor S. Kunin ◽  
Mekhrozhiddin M. Boboev ◽  
Galina I. Nepomnyashchikh ◽  
...  

Proteoglycans (PGs) are expressed on the cell surface and extracellular matrix of all mammalian cells and tissues, playing an important role in cell-cell and cell-matrix interactions and signaling. Changes in the expression and functional properties of individual PGs in prostate cancer are shown, although common patterns of PGs expression in normal and tumour prostate tissues remain unknown. In this study, expression of cell surface and stromal proteoglycans (glypican-1, perlecan, syndecan-1, aggrecan, versican, NG2, brevican, decorin, and lumican) in normal tissue and prostate tumours was determined by RT-PCR analysis and immunostaining with core protein- and GAG-specific antibodies. In normal human prostate tissue, versican, decorin, and biglycan were predominant proteoglycans localised in tissue stroma, and syndecan-1 and glypican-1 were expressed mainly by epithelial cells. In prostate tumours, complex changes in proteoglycans occur, with a common trend towards decrease of decorin and lumican expression, overall increase of syndecan-1 and glypican-1 expression in tumour stroma along with its disappearance in tumour epithelial cells, and aggrecan and NG2 expressions in some prostate tumours. All the changes result in the highly individual proteoglycan expression patterns in different prostate tumours, which may be potentially useful as molecular markers for prostate cancer personalised diagnosis and treatment.


The Prostate ◽  
2013 ◽  
Vol 73 (10) ◽  
pp. 1057-1068 ◽  
Author(s):  
Marie-Odile Guimond ◽  
Marie-Claude Battista ◽  
Fatemeh Nikjouitavabi ◽  
Maude Carmel ◽  
Véronique Barres ◽  
...  

2003 ◽  
Vol 23 (9) ◽  
pp. 1183-1188 ◽  
Author(s):  
İlker Durak ◽  
Hasan Biri ◽  
Aslıhan Avcı ◽  
Sinan Sözen ◽  
Erdinç Devrim

2016 ◽  
Author(s):  
Rogan Magee ◽  
Phillipe Loher ◽  
Aristeidis G. Telonis ◽  
Yohei Kirino ◽  
Isidore Rigoutsos

We evaluated the deep-sequencing (RNA-seq) data from human prostate tissue that were reported in [1] and the tRNA-derived fragments described in the original analysis. Our study of the same RNA-seq datasets reveals a considerably different pool of tRNA fragments, many of them with higher abundances than the fragments reported in [1]. We also evaluated the q-PCR approach proposed in [1]. As the approach lacks 5’-endpoint specificity, it will not estimate correctly the abundance of many of the tRFs that are present in the sampled RNA populations from human prostate tissue.


Sign in / Sign up

Export Citation Format

Share Document